MétaCan
Menu
Back to cohort
Record W2794302045 · doi:10.3747/co.25.4005

Updates from the 2017 American Society of Hematology Annual Meeting: Practice-Changing Studies in Untreated Chronic Lymphocytic Leukemia

2018· article· en· W2794302045 on OpenAlexafffundvenueabout
Carolyn Owen, Cynthia L. Toze, Anna Christofides

Bibliographic record

VenueCurrent Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicChronic Lymphocytic Leukemia Research
Canadian institutionsFluidigm (Canada)Vancouver General HospitalUniversity of British ColumbiaBC Cancer AgencyFoothills Medical CentreImpactUniversity of Calgary
FundersUniversity of Texas MD Anderson Cancer CenterLundbeck CanadaGilead SciencesAstraZeneca
KeywordsIbrutinibObinutuzumabMedicineBendamustineFludarabineVenetoclaxChronic lymphocytic leukemiaRituximabInternal medicineOncologyIGHV@AlemtuzumabHematologyCyclophosphamideMinimal residual diseaseLymphoplasmacytic LymphomaLeukemiaLymphomaChemotherapyWaldenstrom macroglobulinemiaTransplantation

Abstract

fetched live from OpenAlex

The 2017 annual meeting of the American Society of Hematology took place 9–12 December in Atlanta, Georgia. At the meeting, the oral presentations included results from key studies on the first-line treatment of chronic lymphocytic leukemia. A series of phase ii studies focusing on the efficacy and safety of novel treatment strategies were especially notable. One concerned the health-related quality of life results from the gibb study, which had examined the combination of obinutuzumab and bendamustine. A second evaluated the venetoclax–ibrutinib regimen in patients with high-risk disease. The third assessed the combination of ibrutinib, fludarabine, cyclophosphamide, and obinutuzumab in patients with mutated immunoglobulin heavy-chain variable region genes. The fourth examined the combination of ibrutinib, fludarabine, cyclophosphamide, and rituximab in younger patients. And the final study evaluated obinutuzumab–ibrutinib followed by a minimal residual disease strategy in fit patients. Our meeting report describes the foregoing studies and presents interviews with investigators and commentaries by Canadian hematologists about the potential effects on Canadian practice.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.053
metaresearch head score (Gemma)0.129
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.053
Threshold uncertainty score0.278

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0530.129
Meta-epidemiology (narrow)0.0020.001
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0100.011
Science and technology studies0.0030.002
Scholarly communication0.0070.004
Open science0.0030.004
Research integrity0.0090.009
Insufficient payload (model declined to judge)0.0130.005

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.139
GPT teacher head0.471
Teacher spread0.332 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2018
Admission routes4
Has abstractyes

Explore more

Same venueCurrent OncologySame topicChronic Lymphocytic Leukemia ResearchFrench-language works237,207